As always, it was a delight to speak with our Editor-in-Chief, Peter C Taylor (University of Oxford, Oxford, UK). In this interview, we discuss JAK inhibitors and RA-related pain alongside the findings from the FINCH Phase 3 RA clinical trial program of filgotinib. The abstract ‘Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials’ (ABSTRACT NUMBER: 1201) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
1. What are the major unmet needs in terms of pain control in the treatment of rheumatoid arthritis? (0:06)
2. What is the rationale for the use of JAK inhibitors in the treatment of rheumatoid arthritis? (1:49)
3. Could you give us a brief overview of the FINCH clinical studies and the findings? (3.32)
4. Could you tell us about the post-hoc analysis of the FINCH studies data? (4:22)
5. How do you think these findings could impact clinical practice? (10:36)
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Rheumatoid Arthritis
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 1)
We were delighted to speak to Anthony Sebba (Arthritis Associates, FL, USA) to discuss whether pain and inflammation are independent of each other in patients with rheumatoid arthritis. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in […]
Peter C Taylor, ACR 2020 – Therapy Reduction in RA Patients in Remission: The SEAM-RA Trial (Part 1)
Following ACR Convergence 2020 we speak with Peter C Taylor (University of Oxford, Oxford, UK) about his highlights from the meeting. Part 1 in the series covers the SEAM-RA study designed to investigate the effect of therapy reduction in RA patients with persistent submission receiving a combination of methotrexate and etanercept. The abstract entitled ‘Maintenance […]
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 3)
After his presentation at ACR 2020, we spoke with Anthony Sebba (Arthritis Associates, FL, USA) about the importance of studying pain as a patient reported outcome in rheumatoid arthritis and what further studies are needed. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!